Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eleonora Distrutti

Showing results (121-130 of 139) with videos related to

Pageof 14
Sort By:
Pharmacological Research|September 12, 2024
Development of dual GPBAR1 agonist and RORγt inverse agonist for the treatment of inflammatory bowel diseasesMichele Biagioli, Cristina Di Giorgio, Elva Morretta, et al.
Biochemical Pharmacology|March 21, 2025
Allo-lithocholic acid, a microbiome derived secondary bile acid, attenuates liver fibrosisSilvia Marchianò, Michele Biagioli, Cristina Di Giorgio, et al.
Nutrients|August 10, 2019
The Aryl Hydrocarbon Receptor (AhR) Mediates the Counter-Regulatory Effects of Pelargonidins in Models of Inflammation and Metabolic DysfunctionsMichele Biagioli, Adriana Carino, Chiara Fiorucci, et al.
Biochemical Pharmacology|April 19, 2021
Discovery of a AHR pelargonidin agonist that counter-regulates Ace2 expression and attenuates ACE2-SARS-CoV-2 interactionMichele Biagioli, Silvia Marchianò, Rosalinda Roselli, et al.
Gut Microbes|March 19, 2026
A bile acid-GPBAR1 network supports anti-inflammatory and anti-fibrotic benefits of probiotics in colitisMichele Biagioli, Cristina Di Giorgio, Silvia Marchianò, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 9, 2012
Role of nuclear receptors in lipid dysfunction and obesity-related diseasesHollie I Swanson, Taira Wada, Wen Xie, et al.
Cells|November 11, 2022
Repositioning Mifepristone as a Leukaemia Inhibitory Factor Receptor Antagonist for the Treatment of Pancreatic AdenocarcinomaCristina Di Giorgio, Antonio Lupia, Silvia Marchianò, et al.
Frontiers in Oncology|March 31, 2023
Discovery of BAR502, as potent steroidal antagonist of leukemia inhibitory factor receptor for the treatment of pancreatic adenocarcinomaCristina Di Giorgio, Rachele Bellini, Antonio Lupia, et al.
Biochemistry and Biophysics Reports|June 8, 2026
The Farnesoid X receptor-bile acid axis contributes to immune evasion in gastric cancer and its inhibition enhances efficacy of anti-PD-L1 therapyCristina Di Giorgio, Michele Biagioli, Silvia Marchianò, et al.
Translational Oncology|June 8, 2026
Pharmacological inhibition of LIF signaling reverses PD-L1-mediated immune suppression in gastric cancerCristina Di Giorgio, Silvia Marchianò, Michele Biagioli, et al.
Pageof 14

Showing results (121-130 of 139) with videos related to

Sort By:
Pageof 14
Pharmacological Research|September 12, 2024
Development of dual GPBAR1 agonist and RORγt inverse agonist for the treatment of inflammatory bowel diseasesMichele Biagioli, Cristina Di Giorgio, Elva Morretta, et al.
Biochemical Pharmacology|March 21, 2025
Allo-lithocholic acid, a microbiome derived secondary bile acid, attenuates liver fibrosisSilvia Marchianò, Michele Biagioli, Cristina Di Giorgio, et al.
Nutrients|August 10, 2019
The Aryl Hydrocarbon Receptor (AhR) Mediates the Counter-Regulatory Effects of Pelargonidins in Models of Inflammation and Metabolic DysfunctionsMichele Biagioli, Adriana Carino, Chiara Fiorucci, et al.
Biochemical Pharmacology|April 19, 2021
Discovery of a AHR pelargonidin agonist that counter-regulates Ace2 expression and attenuates ACE2-SARS-CoV-2 interactionMichele Biagioli, Silvia Marchianò, Rosalinda Roselli, et al.
Gut Microbes|March 19, 2026
A bile acid-GPBAR1 network supports anti-inflammatory and anti-fibrotic benefits of probiotics in colitisMichele Biagioli, Cristina Di Giorgio, Silvia Marchianò, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 9, 2012
Role of nuclear receptors in lipid dysfunction and obesity-related diseasesHollie I Swanson, Taira Wada, Wen Xie, et al.
Cells|November 11, 2022
Repositioning Mifepristone as a Leukaemia Inhibitory Factor Receptor Antagonist for the Treatment of Pancreatic AdenocarcinomaCristina Di Giorgio, Antonio Lupia, Silvia Marchianò, et al.
Frontiers in Oncology|March 31, 2023
Discovery of BAR502, as potent steroidal antagonist of leukemia inhibitory factor receptor for the treatment of pancreatic adenocarcinomaCristina Di Giorgio, Rachele Bellini, Antonio Lupia, et al.
Biochemistry and Biophysics Reports|June 8, 2026
The Farnesoid X receptor-bile acid axis contributes to immune evasion in gastric cancer and its inhibition enhances efficacy of anti-PD-L1 therapyCristina Di Giorgio, Michele Biagioli, Silvia Marchianò, et al.
Translational Oncology|June 8, 2026
Pharmacological inhibition of LIF signaling reverses PD-L1-mediated immune suppression in gastric cancerCristina Di Giorgio, Silvia Marchianò, Michele Biagioli, et al.
Pageof 14